HK1051805A1 - Tnf-derivd peptides for use in treating oedema - Google Patents

Tnf-derivd peptides for use in treating oedema

Info

Publication number
HK1051805A1
HK1051805A1 HK03103102A HK03103102A HK1051805A1 HK 1051805 A1 HK1051805 A1 HK 1051805A1 HK 03103102 A HK03103102 A HK 03103102A HK 03103102 A HK03103102 A HK 03103102A HK 1051805 A1 HK1051805 A1 HK 1051805A1
Authority
HK
Hong Kong
Prior art keywords
tnf
oedema
alpha
present
peptides
Prior art date
Application number
HK03103102A
Other languages
English (en)
Inventor
Baetselier Patrick De
Rudolf Lucas
Jerome Pugin
Alain Bloc
Lucie Fransen
Original Assignee
Rudolf Lucas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rudolf Lucas filed Critical Rudolf Lucas
Publication of HK1051805A1 publication Critical patent/HK1051805A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK03103102A 1998-08-14 2003-04-30 Tnf-derivd peptides for use in treating oedema HK1051805A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21

Publications (1)

Publication Number Publication Date
HK1051805A1 true HK1051805A1 (en) 2003-08-22

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103102A HK1051805A1 (en) 1998-08-14 2003-04-30 Tnf-derivd peptides for use in treating oedema

Country Status (21)

Country Link
US (2) US20030105021A1 (de)
EP (3) EP1105152A1 (de)
JP (1) JP4542266B2 (de)
CN (1) CN1181886C (de)
AT (2) ATE395072T1 (de)
AU (1) AU764992B2 (de)
BR (1) BR9912899A (de)
CA (1) CA2334941C (de)
CZ (1) CZ302862B6 (de)
DE (2) DE69937206T2 (de)
DK (1) DK1264599T3 (de)
ES (1) ES2296872T3 (de)
HK (1) HK1051805A1 (de)
HU (1) HU227661B1 (de)
IL (2) IL141064A0 (de)
NZ (1) NZ509604A (de)
PL (1) PL203706B1 (de)
PT (1) PT1264599E (de)
TR (1) TR200100338T2 (de)
WO (1) WO2000009149A1 (de)
ZA (1) ZA200100656B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105152A1 (de) 1998-08-14 2001-06-13 Innogenetics N.V. Tnf-abgeleitete peptide zur behandlung von oedema
WO2006013183A1 (en) * 2004-08-06 2006-02-09 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (de) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Neuartige Peptide und ihre Verwendung bei der Behandlung von Ödemen
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT506151B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
EP2397151B1 (de) * 2010-06-21 2015-04-22 Apeptico Forschung Und Entwicklung Gmbh Behandlung vaskulärer Komplikationen von Diabetes
AT510585B1 (de) * 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
EP2679239A1 (de) 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
US20160143266A1 (en) * 2013-04-23 2016-05-26 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical Composition Comprising a Cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
CA2940351A1 (en) 2014-03-18 2015-09-24 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
EP4051307B1 (de) 2020-05-08 2023-02-01 APEPTICO Forschung und Entwicklung GmbH Peptid zur vorbeugung oder behandlung von covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
CA2155103A1 (en) * 1993-02-03 1994-08-18 Rudolph Lucas Tnf-alpha muteins and a process for preparing them
EP1105152A1 (de) 1998-08-14 2001-06-13 Innogenetics N.V. Tnf-abgeleitete peptide zur behandlung von oedema

Also Published As

Publication number Publication date
CN1312724A (zh) 2001-09-12
HUP0103117A3 (en) 2004-03-01
HU227661B1 (hu) 2011-10-28
IL141064A0 (en) 2002-02-10
EP1247531A2 (de) 2002-10-09
US20030185791A1 (en) 2003-10-02
EP1105152A1 (de) 2001-06-13
WO2000009149A1 (en) 2000-02-24
NZ509604A (en) 2003-05-30
CA2334941A1 (en) 2000-02-24
DE69937206D1 (de) 2007-11-08
EP1247531B1 (de) 2008-05-14
ATE374039T1 (de) 2007-10-15
EP1264599B1 (de) 2007-09-26
JP2002522508A (ja) 2002-07-23
ZA200100656B (en) 2005-06-29
DE69938743D1 (de) 2008-06-26
CA2334941C (en) 2011-08-09
CZ302862B6 (cs) 2011-12-21
AU5620999A (en) 2000-03-06
ATE395072T1 (de) 2008-05-15
PL203706B1 (pl) 2009-11-30
CN1181886C (zh) 2004-12-29
BR9912899A (pt) 2001-05-08
DK1264599T3 (da) 2008-02-04
US20030105021A1 (en) 2003-06-05
TR200100338T2 (tr) 2001-12-21
AU764992B2 (en) 2003-09-04
EP1264599A1 (de) 2002-12-11
PL345997A1 (en) 2002-01-14
EP1247531A3 (de) 2002-12-18
IL141064A (en) 2009-09-01
DE69937206T2 (de) 2008-06-19
PT1264599E (pt) 2008-01-07
ES2296872T3 (es) 2008-05-01
US7258861B2 (en) 2007-08-21
JP4542266B2 (ja) 2010-09-08
CZ2001538A3 (cs) 2001-08-15
HUP0103117A2 (hu) 2001-12-28

Similar Documents

Publication Publication Date Title
PL345997A1 (en) Tnf-derived peptides for use in treating oedema
HU902697D0 (en) Process for the enzymatic removal of the n-terminal sequence of proteins
IL161591A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
MX9606013A (es) Lacasas purificadas de myceliophthora y acidos nucleicos que codifican para las mismas.
CA2184908A1 (en) Human osteoclast-derived cathepsin
AU2672900A (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
IL187907A0 (en) Analogues of glp-1 and uses thereof
IL143481A0 (en) Glp-1 analogues
IL159903A0 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2002015922A3 (en) New uses for amino acid anticonvulsants for treatment of pain
WO2002097030A3 (en) Peptides derived from neural thread proteins and their medical use
GB2367061A (en) Peptides
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
GR3015817T3 (en) Substituted alpha-amino acids having pharmaceutical activity.
DE69329899T2 (de) Behandlung von tropikalischer spastischer Paresis mit Peptide T
ATE409492T1 (de) Zusammensetzung zur vermeidung und behandlung von cellulitis
ATE310091T1 (de) Carboxypeptidasen aus aspergillus oryzae und diese kodierende nukleinsäuren
DE69524415T2 (de) UNGESPLEISSTE VARIANTEN DES gp350/220
ATE218334T1 (de) Verwendung von gabapentin in der behandlung vonangst - und panikstörungen
GB9604518D0 (en) Novel compounds